Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel B2C (Patient, Caregiver), B2B ( Providers, Payer, Employer, Pharma) - Global Forecasts to 2027

DTx(デジタル治療)のグローバル市場予測(~2027):治療/介護用、予防用

◆タイトル:Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel B2C (Patient, Caregiver), B2B ( Providers, Payer, Employer, Pharma) - Global Forecasts to 2027
◆商品コード:HIT4407-22
◆調査・発行会社:MarketsandMarkets
◆発行日:2022年10月24日
◆ページ数:224
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥0見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥0見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥0見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社によると、世界のDTx(デジタル治療)市場規模は、2022年45億ドルから2027年177億ドルまで年平均31.6%成長すると予測されています。本調査レポートは、DTx(デジタル治療)の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、用途別(治療/介護用、予防用)分析、販売チャネル別(B2B、B2C)分析、地域別(北米、ヨーロッパ、アジア太平洋、その他地域)分析、競争状況などの項目を掲載しています。なお、本レポートに掲載されている企業情報には、Noom, Inc (US)、Teladoc Health, Inc. (US)、Omada Health, Inc. (US)、WellDoc, Inc (US)、Pear Therapeutics, Inc. (US)、CogniFit Inc (US)、Ginger (US)、Propeller Health (US)、2Morrow, Inc. (US)、Canary Health (US)、Click Therapeutics, Inc. (US)、Akili, Inc. (US)などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要

・世界のDTx(デジタル治療)市場規模:用途別
- 治療/介護における市場規模
- 予防における市場規模

・世界のDTx(デジタル治療)市場規模:販売チャネル別
- B2Bの市場規模
- B2Cの市場規模

・世界のDTx(デジタル治療)市場規模:地域別
- 北米のDTx(デジタル治療)市場規模
- ヨーロッパのDTx(デジタル治療)市場規模
- アジア太平洋のDTx(デジタル治療)市場規模
- その他地域のDTx(デジタル治療)市場規模

・競争状況
・企業情報

“The global digital therapeutics market is projected to reach USD 17.7 billion by 2027 from USD 4.5 billion in 2022, at a CAGR of 31.6% during the forecast period. ”
The adoption of digital therapeutics is growing at a fast pace owing to factors such as rise in number of patients with chronic diseases and growing investments in digital therapeutics. However, a lack of awareness and access to digital therapeutics programs in developing countries, resistance from traditional healthcare providers, and uneven payment models are challenging the growth of this market.
Treatment/care-related applications segment hold the largest share of the digital therapeutics market in 2021
On the basis of application, the digital therapeutics market is divided into preventive and treatment/care-related applications. The large share of this segment is attributed to the rising investments in digital therapeutics to promote the development of cost-effective and scalable treatment platforms for these conditions.

“Diabetes segment is expected to grow at the highest rate during the forecast period”
On the basis of type of treatment/care-related application, the digital therapeutics market is further dividedinto diabetes, CNS disorders, chronic respiratory diseases, musculoskeletal disorders, cardiovascular diseases, smoking cessation, medication adherence, gastrointestinal disorders, substance use disorders & addiction management, rehabilitation & patient care, and other treatment/care-related applications. In 2021, diabetes commanded the largest share of the digital therapeutics market for treatment/care-related applications. The increasing prevalence of diabetes, high healthcare costs associated with diabetes, and rising government initiatives to decrease the burden with the help of cost-effective solutions are expected to drive the market growth in this segment.

“B2B segment is expected to grow with the highest CAGR during the forecast period”
On the basis of sales channel, the digital therapeutics market is divided into business-to-customer (B2C) and business-to-business (B2B). This is attributed to growing inclination of pharma companies to integrate digital therapeutics with their drug products.

“North America to be the largest and the fastest-growing regional market”
North America, which includes the US and Canada, holds the largest market share for digital therapeutics in 2021. Factors such as the improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 (50%), Tier 2 (30%), and Tier 3 (20%)
• By Designation: C-level (75%), D-level (15%), and Others (10%)
• By Region: North America (70%), Europe (20%), APAC (7%), and the RoW (3%)

The prominent players in this market are Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Pear Therapeutics, Inc. (US), CogniFit Inc (US), Ginger (US), Propeller Health (US), 2Morrow, Inc. (US), Canary Health (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt. Ltd. (India), Twill Inc. (US), Better Therapeutics, Inc (US), Mindstrong (US), Kaia Health (Germany), BehaVR Inc (US), Ayogo (Canada), Mindable Health GmbH (Germany), Virta Health Corp (US), Hinge Health, Inc. (US), Orexo AB (Sweden) and Freespira (US).

Research Coverage:
This report provides a study of the digital therapeutics market. It aims at estimating the size and future growth potential of the market across different segments, such as sales channel, application, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall digital therapeutics market and its subsegments. This report will also help stakeholders understand the competitive landscape, gain insights to position their business, and make suitable go-to-market strategies. It will also enable stakeholders to gauge the pulse of the market and provide them with information on the key market drivers, restraints, opportunities and challenges.

【レポートの目次】

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS AND EXCLUSIONS 30
1.3 MARKET SCOPE 31
1.4 YEARS CONSIDERED 31
1.5 CURRENCY CONSIDERED 32
1.6 STAKEHOLDERS 32
1.7 LIMITATIONS 32
1.8 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
FIGURE 1 RESEARCH DESIGN 34
2.1.1 SECONDARY DATA 35
2.1.1.1 Key data from secondary sources 35
2.1.2 PRIMARY DATA 36
FIGURE 2 PRIMARY SOURCES 36
2.1.2.1 Key data from primary sources 37
FIGURE 3 KEY INDUSTRY INSIGHTS 38
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY TYPE OF BUYER AND REGION 39
2.2 MARKET SIZE ESTIMATION 40
2.2.1 BOTTOM-UP APPROACH 40
2.2.1.1 Approach one: Revenue mapping-based estimation 40
FIGURE 6 DIGITAL THERAPEUTICS: REVENUE MAPPING-BASED ESTIMATION 41
2.2.1.2 Approach two: Buyer adoption-based estimation 41
FIGURE 7 DIGITAL THERAPEUTICS ESTIMATION: BUYER ADOPTION-BASED ESTIMATION 41
2.2.2 TOP-DOWN APPROACH: PENETRATION RATE-BASED MARKET SIZE ESTIMATION 42
FIGURE 8 PENETRATION RATE-BASED MARKET ESTIMATION 42
2.2.3 GROWTH FORECAST 42
TABLE 1 FACTOR ANALYSIS 43
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 44
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 45
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 45
FIGURE 11 DATA TRIANGULATION METHODOLOGY 46
2.4 ASSUMPTIONS 46
2.5 RISK ASSESSMENT 47
3 EXECUTIVE SUMMARY 48
FIGURE 12 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2022 VS. 2027 (USD MILLION) 48
FIGURE 13 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, 2022 VS. 2027 (USD MILLION) 49
FIGURE 14 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, 2022–2027 49
FIGURE 15 DIGITAL THERAPEUTICS MARKET, BY APPLICATION (2022–2027) 50
FIGURE 16 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, 2022 VS. 2027 (USD MILLION) 51
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF DIGITAL THERAPEUTICS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 DIGITAL THERAPEUTICS MARKET OVERVIEW 53
FIGURE 18 INCREASING INCIDENCE OF CHRONIC DISEASES & TECHNOLOGICAL ADVANCEMENTS TO DRIVE ADOPTION OF DIGITAL THERAPEUTICS 53
4.2 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2022–2027 54
FIGURE 19 B2B SALES DOMINATE DIGITAL THERAPEUTICS MARKET 54
4.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 55
FIGURE 20 NORTH AMERICA TO GROW AT HIGHEST RATE 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
FIGURE 21 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
5.2.1 DRIVERS 57
5.2.1.1 Increasing incidence of preventable chronic diseases 57
5.2.1.2 Rising focus on preventive healthcare 57
5.2.1.3 Need to control healthcare costs 58
5.2.1.4 Significant increase in venture capital investments 58
5.2.1.5 Benefits of digital therapeutics 59
5.2.1.5.1 Ability to induce behavioral change 59
5.2.1.5.2 Improved drug adherence 60
5.2.1.5.3 Patient convenience and user-friendliness 60
5.2.2 RESTRAINTS 60
5.2.2.1 Patient data privacy concerns 60
5.2.3 OPPORTUNITIES 61
5.2.3.1 Emerging markets 61
5.2.3.2 Large undiagnosed and untreated population 61
5.2.3.3 Unexplored therapeutic applications 62
5.2.4 CHALLENGES 62
5.2.4.1 Unstable payment models 62
5.2.4.2 Reluctance among patients to adopt digital therapeutics 62
5.2.4.3 Lack of awareness and access to digital therapeutics programs in developing countries 63
5.2.4.4 Resistance from traditional healthcare providers 63
5.3 SUPPLY/VALUE CHAIN ANALYSIS 63
FIGURE 22 VALUE CHAIN ANALYSIS 64
5.4 ECOSYSTEM ANALYSIS 65
FIGURE 23 ECOSYSTEM ANALYSIS 65
5.5 PIPELINE PRODUCTS 66
5.6 CASE STUDIES 67
5.7 PORTER’S FIVE FORCES ANALYSIS 68
5.7.1 THREAT OF NEW ENTRANTS 68
5.7.2 BARGAINING POWER OF SUPPLIERS 68
5.7.3 BARGAINING POWER OF BUYERS 69
5.7.4 THREAT OF SUBSTITUTES 69
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 69
5.8 REGULATORY LANDSCAPE 69
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 2 DIGITAL THERAPEUTICS REGULATORY FRAMEWORK 70
TABLE 3 DIGITAL THERAPEUTICS MARKET: REGULATORY DATA NEEDED FOR CLASS II DEVICES 71
5.9 TECHNOLOGY TRENDS 72
TABLE 4 TECHNOLOGY ENABLERS, BENEFITS, AND EXAMPLES 72
5.10 INDUSTRY TRENDS 72
5.10.1 VIRTUAL REALITY 72
5.10.2 INCREASING DEMAND FOR DIGITAL DELIVERY OF BEHAVIORAL THERAPY 73
5.10.3 GROWING COLLABORATIONS BETWEEN STAKEHOLDERS 73
TABLE 5 DIGITAL THERAPEUTICS: RECENT COLLABORATIONS 73
5.11 PRICING ANALYSIS & REIMBURSEMENT SCENARIO 74
5.11.1 AVERAGE SELLING PRICE 74
TABLE 6 DIGITAL THERAPEUTICS PRODUCTS: REIMBURSEMENT & PRICE BY COUNTRY 74
5.11.2 REIMBURSEMENT SCENARIO 74
TABLE 7 DIGITAL THERAPEUTICS: GLOBAL COVERAGE DETERMINATION STANDARDS 75
5.12 PATENT ANALYSIS 76
5.13 KEY CONFERENCES AND EVENTS IN 2022–2023 76
TABLE 8 DIGITAL THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 76
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 77
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 77
FIGURE 24 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL 77
TABLE 9 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL 78
5.14.2 BUYING CRITERIA 78
FIGURE 25 KEY BUYING CRITERIA FOR SALES CHANNEL 78
TABLE 10 KEY BUYING CRITERIA FOR SALES CHANNEL 79
6 DIGITAL THERAPEUTICS MARKET, BY APPLICATION 80
6.1 INTRODUCTION 81
TABLE 11 DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 81
6.2 TREATMENT/CARE-RELATED APPLICATIONS 81
TABLE 12 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 82
TABLE 13 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 82
6.2.1 DIABETES 83
6.2.1.1 Rising prevalence of diabetes to drive market growth 83
TABLE 14 DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2020–2027 (USD MILLION) 83
6.2.2 CENTRAL NERVOUS SYSTEM DISORDERS 83
TABLE 15 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 16 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY REGION, 2020–2027 (USD MILLION) 84
6.2.2.1 Mental health disorders 84
6.2.2.1.1 Benefits of digital therapeutics in managing mental health disorders to drive R&D 84
TABLE 17 DIGITAL THERAPEUTICS MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2020–2027 (USD MILLION) 85
6.2.2.2 Other CNS disorders 85
TABLE 18 DIGITAL THERAPEUTICS MARKET FOR OTHER CNS DISORDERS, BY REGION, 2020–2027 (USD MILLION) 85
6.2.3 SMOKING CESSATION 86
6.2.3.1 Focus on providing validated, effective mobile applications to help quit smoking to aid market growth 86
TABLE 19 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2020–2027 (USD MILLION) 86
6.2.4 CHRONIC RESPIRATORY DISEASES 86
6.2.4.1 Growing prevalence of COPD and asthma to drive market growth 86
TABLE 20 DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES, BY REGION, 2020–2027 (USD MILLION) 87
6.2.5 MUSCULOSKELETAL DISORDERS 87
6.2.5.1 Dearth of physiotherapists to support market growth 87
TABLE 21 DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 87
6.2.6 CARDIOVASCULAR DISEASE 88
6.2.6.1 High burden of CVD to drive demand for digital therapeutics solutions 88
TABLE 22 DIGITAL THERAPEUTICS MARKET FOR CVD, BY REGION, 2020–2027 (USD MILLION) 88
6.2.7 MEDICATION ADHERENCE 88
6.2.7.1 Growing number of medication non-adherence cases to propel market growth 88
TABLE 23 DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2020–2027 (USD MILLION) 89
6.2.8 GASTROINTESTINAL DISORDERS 89
6.2.8.1 High prevalence of gastrointestinal disorders to ensure strong interest in developing targeted solutions 89
TABLE 24 DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2020–2027 (USD MILLION) 89
6.2.9 REHABILITATION & PATIENT CARE 90
6.2.9.1 Benefits of digital therapeutics have induced startups to develop platforms for patient care 90
TABLE 25 DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE, BY REGION, 2020–2027 (USD MILLION) 90
6.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT 90
6.2.10.1 Potential to improve efficiency of behavioral interventions to drive market growth 90
TABLE 26 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2020–2027 (USD MILLION) 91
6.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS 91
TABLE 27 DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 91
6.3 PREVENTIVE APPLICATIONS 92
TABLE 28 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 92
TABLE 29 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 93
6.3.1 PREDIABETES 93
6.3.1.1 Influx of startups to provide effective prevention against prediabetes to support market 93
TABLE 30 DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION, 2020–2027 (USD MILLION) 93
6.3.2 OBESITY 94
6.3.2.1 Availability of cost-effective solutions for obesity management to propel market growth 94
TABLE 31 DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2020–2027 (USD MILLION) 94
6.3.3 NUTRITION 94
6.3.3.1 Importance of nutrition in preventing a wide range of ailments to drive demand for digital therapeutic solutions 94
TABLE 32 DIGITAL THERAPEUTICS MARKET FOR NUTRITION, BY REGION, 2020–2027 (USD MILLION) 95
6.3.4 LIFESTYLE MANAGEMENT 95
6.3.4.1 Ability of digital therapeutics solutions to induce positive behavioral changes to contribute to rising demand 95
TABLE 33 DIGITAL THERAPEUTICS MARKET FOR LIFESTYLE MANAGEMENT, BY REGION, 2020–2027 (USD MILLION) 96
6.3.5 OTHER PREVENTIVE APPLICATIONS 96
TABLE 34 DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 97
7 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL 98
7.1 INTRODUCTION 99
TABLE 35 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 99
7.2 B2B 99
TABLE 36 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 99
TABLE 37 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY REGION, 2020–2027 (USD MILLION) 100
7.2.1 PAYERS 100
7.2.1.1 Payers to hold largest share of B2B market 100
TABLE 38 DIGITAL THERAPEUTICS MARKET FOR PAYERS, BY REGION, 2020–2027 (USD MILLION) 101
7.2.2 EMPLOYERS 101
7.2.2.1 Rising importance of employee health management to drive adoption of digital therapeutics among employers 101
TABLE 39 DIGITAL THERAPEUTICS MARKET FOR EMPLOYERS, BY REGION, 2020–2027 (USD MILLION) 102
7.2.3 PHARMACEUTICAL COMPANIES 102
7.2.3.1 Growing cross-industry collaborations between digital therapeutics start-ups and pharmaceutical companies to drive market growth 102
TABLE 40 DIGITAL THERAPEUTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION) 103
7.2.4 PROVIDERS 103
7.2.4.1 Potential for better patient management and cost-reduction to drive demand for digital therapeutics among providers 103
TABLE 41 DIGITAL THERAPEUTICS MARKET FOR PROVIDERS, BY REGION, 2020–2027 (USD MILLION) 104
7.2.5 OTHER BUYERS 104
TABLE 42 DIGITAL THERAPEUTICS MARKET FOR OTHER BUYERS, BY REGION, 2020–2027 (USD MILLION) 104
7.3 B2C 104
TABLE 43 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 105
TABLE 44 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY REGION, 2020–2027 (USD MILLION) 105
7.3.1 CAREGIVERS 105
7.3.1.1 Ease of managing health conditions to drive demand for solutions among caregivers 105
TABLE 45 DIGITAL THERAPEUTICS MARKET FOR CAREGIVERS, BY REGION, 2020–2027 (USD MILLION) 106
7.3.2 PATIENTS 106
7.3.2.1 Awareness of preventive health among patients to support segment growth 106
TABLE 46 DIGITAL THERAPEUTICS MARKET FOR PATIENTS, BY REGION, 2020–2027 (USD MILLION) 106
8 DIGITAL THERAPEUTICS MARKET, BY REGION 107
8.1 INTRODUCTION 108
TABLE 47 DIGITAL THERAPEUTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 108
8.2 NORTH AMERICA 108
FIGURE 26 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT 109
TABLE 48 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 110
TABLE 49 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 110
TABLE 50 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 51 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 111
TABLE 52 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 53 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 112
TABLE 54 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 112
TABLE 55 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 113
8.2.1 US 113
8.2.1.1 Strong start-up base to ensure high product access for end users 113
TABLE 56 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114
TABLE 57 US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 58 US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 115
TABLE 59 US: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 116
TABLE 60 US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 116
TABLE 61 US: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 116
TABLE 62 US: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 117
8.2.2 CANADA 117
8.2.2.1 Government initiatives to support digital therapeutics to drive market growth in Canada 117
TABLE 63 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 118
TABLE 64 CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 65 CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 66 CANADA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 119
TABLE 67 CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 119
TABLE 68 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 120
TABLE 69 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 120
8.3 EUROPE 120
FIGURE 27 EUROPE: DIGITAL THERAPEUTICS MARKET SNAPSHOT 121
TABLE 70 EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 122
TABLE 71 EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 122
TABLE 72 EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 73 EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 74 EUROPE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 124
TABLE 75 EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 124
TABLE 76 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 124
TABLE 77 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 125
8.3.1 GERMANY 125
8.3.1.1 Germany forms largest market for digital therapeutics in Europe due to supportive government initiatives 125
TABLE 78 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126
TABLE 79 GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 126
TABLE 80 GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 81 GERMANY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 127
TABLE 82 GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 127
TABLE 83 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 128
TABLE 84 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 128
8.3.2 UK 128
8.3.2.1 Well-established healthcare system and government support to propel market 128
TABLE 85 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 129
TABLE 86 UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 87 UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 88 UK: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 131
TABLE 89 UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 131
TABLE 90 UK: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 131
TABLE 91 UK: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 132
8.3.3 FRANCE 132
8.3.3.1 Growing healthcare expenditure and favorable health insurance system to support market 132
TABLE 92 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 133
TABLE 93 FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 133
TABLE 94 FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 95 FRANCE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 134
TABLE 96 FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 134
TABLE 97 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 135
TABLE 98 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 135
8.3.4 SPAIN 135
8.3.4.1 Initiatives by emerging digital therapeutics startups to drive market 135
TABLE 99 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 136
TABLE 100 SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 101 SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 137
TABLE 102 SPAIN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 137
TABLE 103 SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 137
TABLE 104 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 138
TABLE 105 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 138
8.3.5 ITALY 138
8.3.5.1 Need for alternative and effective treatment to drive market 138
TABLE 106 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 107 ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 108 ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 109 ITALY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 110 ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 140
TABLE 111 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 141
TABLE 112 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 141
8.3.6 REST OF EUROPE 141
TABLE 113 ROE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 114 ROE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 142
TABLE 115 ROE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 116 ROE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 117 ROE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 143
TABLE 118 ROE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 144
TABLE 119 ROE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 144
8.4 ASIA PACIFIC 145
TABLE 120 APAC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 121 APAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 122 APAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 123 APAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 124 APAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 125 APAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 147
TABLE 126 APAC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 147
TABLE 127 APAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 148
8.4.1 JAPAN 148
8.4.1.1 Rising diabetes incidence and collaborations to drive market growth 148
TABLE 128 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 148
TABLE 129 JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 130 JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 149
TABLE 131 JAPAN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 132 JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 150
TABLE 133 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 150
TABLE 134 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 151
8.4.2 CHINA 151
8.4.2.1 Growing geriatric population and incidence of chronic conditions to drive demand 151
TABLE 135 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 151
TABLE 136 CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 137 CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 138 CHINA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 153
TABLE 139 CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 153
TABLE 140 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 153
TABLE 141 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 154
8.4.3 INDIA 154
8.4.3.1 Rising chronic disease incidence and need for better disease management to drive market 154
TABLE 142 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 155
TABLE 143 INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 144 INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 145 INDIA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 156
TABLE 146 INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 156
TABLE 147 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 157
TABLE 148 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 157
8.4.4 REST OF ASIA PACIFIC 157
TABLE 149 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 150 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 158
TABLE 151 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 152 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 153 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 159
TABLE 154 ROAPAC DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 160
TABLE 155 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 160
8.5 REST OF THE WORLD 160
TABLE 156 ROW: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 161
TABLE 157 ROW: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 161
TABLE 158 ROW: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 159 ROW: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 160 ROW: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020–2027 (USD MILLION) 162
TABLE 161 ROW: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 163
TABLE 162 ROW: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020–2027 (USD MILLION) 163
9 COMPETITIVE LANDSCAPE 164
9.1 OVERVIEW 164
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 164
FIGURE 28 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL THERAPEUTICS 165
9.3 MARKET SHARE ANALYSIS 166
TABLE 163 DIGITAL THERAPEUTICS MARKET: DEGREE OF COMPETITION 166
FIGURE 29 MARKET SHARE ANALYSIS: DIGITAL THERAPEUTICS MARKET 167
9.4 MARKET RANKING ANALYSIS, 2022 167
FIGURE 30 DIGITAL THERAPEUTICS MARKET RANKING ANALYSIS, 2022 167
9.5 COMPETITIVE BENCHMARKING 168
TABLE 164 DIGITAL THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 168
TABLE 165 DIGITAL THERAPEUTICS MARKET: SALES CHANNEL FOOTPRINT OF KEY PLAYERS 169
TABLE 166 DIGITAL THERAPEUTICS MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS 169
9.5.1 COMPANY EVALUATION MATRIX: DEFINITIONS AND METHODOLOGY 169
TABLE 167 DIGITAL THERAPEUTICS MARKET: CRITERIA CONSIDERED FOR EVALUATION 169
9.5.1.1 Stars 170
9.5.1.2 Emerging leaders 170
9.5.1.3 Pervasive players 170
9.5.1.4 Participants 170
FIGURE 31 DIGITAL THERAPEUTICS MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2022 171
9.5.2 COMPETITIVE LEADERSHIP MAPPING: START-UPS/SMES (2022) 172
9.5.2.1 Progressive companies 172
9.5.2.2 Starting blocks 172
9.5.2.3 Responsive companies 172
9.5.2.4 Dynamic companies 172
FIGURE 32 DIGITAL THERAPEUTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2022 173
9.6 COMPETITIVE SCENARIO 174
TABLE 168 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2019– AUGUST 2022 174
9.6.1 DEALS 175
TABLE 169 DIGITAL THERAPEUTICS MARKET: DEALS, JANUARY 2019 – AUGUST 2022 175
9.6.2 OTHER DEVELOPMENTS 176
TABLE 170 DIGITAL THERAPEUTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2019 – AUGUST 2022 176
10 COMPANY PROFILES 177
10.1 KEY PLAYERS 177
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 NOOM 177
TABLE 171 NOOM: BUSINESS OVERVIEW 177
10.1.2 TELADOC HEALTH 180
TABLE 172 TELADOC HEALTH: BUSINESS OVERVIEW 180
FIGURE 33 TELADOC HEALTH: COMPANY SNAPSHOT (2021) 180
10.1.3 OMADA HEALTH 183
TABLE 173 OMADA HEALTH: BUSINESS OVERVIEW 183
10.1.4 WELLDOC 186
TABLE 174 WELLDOC: BUSINESS OVERVIEW 186
10.1.5 PEAR THERAPEUTICS 189
TABLE 175 PEAR THERAPEUTICS: BUSINESS OVERVIEW 189
10.1.6 COGNIFIT 194
TABLE 176 COGNIFIT: BUSINESS OVERVIEW 194
10.1.7 GINGER 196
TABLE 177 GINGER: BUSINESS OVERVIEW 196
10.1.8 PROPELLER HEALTH 198
TABLE 178 PROPELLER HEALTH: BUSINESS OVERVIEW 198
10.1.9 2MORROW 199
TABLE 179 2MORROW: BUSINESS OVERVIEW 199
10.1.10 CANARY HEALTH 201
TABLE 180 CANARY HEALTH: BUSINESS OVERVIEW 201
10.1.11 CLICK THERAPEUTICS 203
TABLE 181 CLICK THERAPEUTICS: BUSINESS OVERVIEW 203
10.1.12 AKILI 205
TABLE 182 AKILI: BUSINESS OVERVIEW 205
10.1.13 WELLTHY THERAPEUTICS 207
TABLE 183 WELLTHY THERAPEUTICS: BUSINESS OVERVIEW 207
10.1.14 COGNOA 209
TABLE 184 COGNOA: BUSINESS OVERVIEW 209
10.1.15 TWILL 211
TABLE 185 TWILL: BUSINESS OVERVIEW 211
10.1.16 KAIA HEALTH 213
TABLE 186 KAIA HEALTH: BUSINESS OVERVIEW 213
10.1.17 BETTER THERAPEUTICS 215
TABLE 187 BETTER THERAPEUTICS: BUSINESS OVERVIEW 215
10.1.18 MINDSTRONG HEALTH 217
TABLE 188 MINDSTRONG HEALTH: BUSINESS OVERVIEW 217
10.1.19 BEHAVR 218
TABLE 189 BEHAVR: BUSINESS OVERVIEW 218
10.1.20 AYOGO 220
TABLE 190 AYOGO: BUSINESS OVERVIEW 220
10.2 OTHER PLAYERS 221
10.2.1 MINDABLE HEALTH 221
10.2.2 VIRTA HEALTH CORP 221
10.2.3 HINGE HEALTH 222
10.2.4 OREXO AB 222
10.2.5 FREESPIRA 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX 224
11.1 DISCUSSION GUIDE 224
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 228
11.3 CUSTOMIZATION OPTIONS 230
11.4 RELATED REPORTS 230
11.5 AUTHOR DETAILS 231



★調査レポート[DTx(デジタル治療)のグローバル市場予測(~2027):治療/介護用、予防用] ( Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel B2C (Patient, Caregiver), B2B ( Providers, Payer, Employer, Pharma) - Global Forecasts to 2027 / HIT4407-22) 販売に関する免責事項
[DTx(デジタル治療)のグローバル市場予測(~2027):治療/介護用、予防用] ( Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel B2C (Patient, Caregiver), B2B ( Providers, Payer, Employer, Pharma) - Global Forecasts to 2027 / HIT4407-22) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆